ArticleBiochemia medica2026
Optimization of icterus interference thresholds for 45 parameters on the Atellica analyzers CH930 and IM1300.
Article in Biochemia medica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The data provided by the manufacturer regarding icterus interference on the various parameters measured on Atellica analyzers are very incomplete, potentially leading to erroneous result interpretation. We aimed to evaluate icterus interference on Atellica CH930 and IM1300 for 45 parameters and to suggest revised icterus indexes for a better interpretation of results. Materials and methods: Pools of serum or plasma were spiked with various concentrations of either conjugated or unconjugated bilirubin. Analytes were measured in triplicate on bilirubin-spiked and native samples. Biases were calculated as the difference between the mean results of both samples. We compared the observed biases to the threshold of 10% similar to the manufacturer, and also to the total allowable errors recommended by the European Biological Variation Study (EuBIVAS). Results: Based on significant bias above 10%, revised icterus index thresholds were higher than manufacturer recommendations for 33 parameters, and lower for 3 parameters. Based on the EuBIVAS criteria, the thresholds were higher than manufacturer recommendations for 33 parameters, and lower for 5 parameters. The revised thresholds differed between the 2 evaluation methods in 13 cases, being less strict for some parameters with the EuBIVAS criteria, and stricter for other ones. For some parameters, the magnitude of interference differed for conjugated and unconjugated bilirubin, or depended on the concentration of the analyte. Conclusions: This work provides important data that can be used to improve the interpretation of results for 45 parameters on Atellica analyzers CH930 and IM1300 in patients with hyperbilirubinemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.